HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-

HCID 9410
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
314-19-2
Standard SMILES
CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3.Cl
InChIKey
SKYZYDSNJIOXRL-BTQNPOSSSA-N
Molecular formula
C17H18ClNO2
Average molar mass
303.8 g/mol
Monoisotopic mass
303.1026065

Overview

See also: Apomorphine Hydrochloride (annotation moved to).

Names & identifiers

Preferred name
4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-
IUPAC
(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol;hydrochloride
English name
Apomorphine hydrochloride
Molecular formula
C17H18ClNO2
Molecular weight
303.78

Names & synonyms

(-)-Apomorphine hydrochloride4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-RefChem:527368314-19-2(R)-(-)-Apomorphine hydrochlorideApomorphine chlorideApomorphinium chlorideApomorphine hydrochloride anhydrous(-)-Apomorphine (hydrochloride)9K13MD7A0DApomorphine.HCl
Show more names
APOMORPHINE HCLAPL-130277(?)-Apomorphine(r)-idUPRIMATAK251)KW-6500R(–)-APONSC 11442APL130277
R-(-)-Apomorphine hydrochlorideApomorphine SLBritajectNSC-11442Apomorphin hydrochloridpomorphini hydrochloridumApomorphinum hydrochloricum(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol;hydrochloride

Properties

Computed structural properties

Topological polar surface area
43.7 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
3
Rotatable bonds
0
Heavy atoms
21
Formal charge
0
Complexity
374

Experimental & physicochemical properties

Collision Cross Section161.7 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Melting point
250 ℃ · >250℃
storage temp.
Store at RT
solubility
1.08 mg/mL · ≥1.08 mg/mL in EtOH with ultrasonic; ≥12.9 mg/mL in DMSO; ≥5.12 mg/mL in H2O
form
solid
FDA UNII
9 K13MD7A0D · 9K13MD7A0D
EPA Substance Registry System
Apomorphine hydrochloride (314-19-2)
Protein binding
90 % · 90%
Excreted unchanged in urine
2 % · <2%
Volume of distribution
2 · 2-19(L/kg)
Biological half-life
29.1 · 29.1-36.9 minutes
Symbol(GHS)
7 · GHS07
Signal word
Warning

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Hazard information

Other Safety InformationIMAP assessments - 4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride, (R)-: Environment tier I assessment

Safety data

tsca
TSCA listed
ridadr
3249
Toxicity
mmo-sat 20 mg/plate MUREAV 137,17,84
Signal word
Warning
Symbol(GHS)
GHS07
hazard_class
6.1(b)
packing_group
III
Hazard statements
H302-H334-H312-H332-H317
Precautionary statements
P264-P270-P301+P312-P330-P501-P261-P271-P304+P340-P312-P280-P302+P352-P312-P322-P363-P501-P261-P272-P280-P302+P352-P333+P313-P321-P363-P501-P261-P285-P304+P341-P342+P311-P501

Chemistry & industry

Uses & manufacturing

General Manufacturing Information4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-: INACTIVE
Applications · 3 items

UsesEmetic.

Uses(R)-(-)-Apomorphine Hydrochloride is a prototypical dopamine agonist. Potential treatment for Parkinson’s disease.

General DescriptionApomorphine hydrochloride,(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolone-10,11-diol hydrochloride (Apokyn), is awhite or off-white powder or crystal soluble in hot water(pKa=8.92). Apormorphine is an aporphine alkaloid of thebenzoquinoline class. Oral apomorphine is poorly absorbedand has a bioavailability of less than 4%. Upon subcutaneousadministration, apomorphine is completely absorbed. Within10 to 20 minutes, the maximum concentration of the drug isdistributed from the blood plasma to the CSF. Other potentialroutes of administration include continuous subcutaneous infusion,intravenous infusion, intranasal spray application,sublingual, and rectal administration.23 The agent is highlylipophilic in nature, allowing for rapid diffusion across theBBB after injection. Apomorphine has a short plasma halflife;however, clinical effects may last from 60 to 90 minutes.Apomorphine displays a significant degree of interpatientvariability in its pharmacokinetic profile. Studies of bothintravenous and subcutaneous injection routes found this variation was not attributable to body weight, age, gender,and duration of PD or L-DOPA dose/duration alone.Apomorphine is extensively metabolized. Hypothesizedroutes include sulfation, N-demethylation, glucuronidation,and oxidation. Subcutaneous injections of apomorphine arerenally and hepatically cleared, with the majority appearingto be renally cleared. Dosage adjustments are needed in bothliver and renal impairment. The activity of apomorphine isbelieved to be caused by stimulation of postsynaptic D1- andD2-type receptors within the caudate/putamen in the brain.Apomorphine is indicated for the acute, intermittent treatmentof hypomobility, “off” episodes (“end-of-dose wearingoff” and unpredictable on/off episodes) associated with advancedPD.

Upstream & downstream products

Related reactions

5 records
New reaction record
HRID 520276 reaction equation
HRID 520276As reactant
HRID 520277 reaction equation
HRID 520277As reactant
HRID 1585445 reaction equation
HRID 1585445As reactant
HRID 2167017 reaction equation
HRID 2167017As reactant
HRID 2167018 reaction equation
HRID 2167018As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
314-19-2
PubChem CID
9410
DTXSID
DTXSID5040598
UNII
9K13MD7A0D
Hazard statements
302 · H302-H334-H312-H332-H317
Precautionary statements
264 · P264-P270-P301+P312-P330-P501-P261-P271-P304+P340-P312-P280-P302+P352-P312-P322-P363-P501-P261-P272-P280-P302+P352-P333+P313-P321-P363-P501-P261-P285-P304+P341-P342+P311-P501
RIDADR
3249 · 3249
TSCA
TSCA listed
HazardClass
6.1 · 6.1(b)
PackingGroup
III
Toxicity
20 mg/plate · mmo-sat 20 mg/plate MUREAV 137,17,84

Upstream raw materials

Phosphoric acidMORPHINE